4,901 trials
Epilepsy
Primary: The Maximum Observed Plasma Concentration (Cmax) of Padsevonil (PSL) During the Study — 1210; 1670 ng/mL
Healthy Adult Volunteers
Primary: Serious Adverse Events — 0; 0; 0; 0 Participants
Iron Deficiency, Anaemia in Children · Iron-Deficiency
Primary: Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 1 — 2.4518; 1.1632; 0.5299 mg/L
Healthy Volunteers
Primary: Maximum Observed Plasma Concentration (Cmax) of RO7017773 (Part 1) — 1320; 1570; 1120; 1490 ng/mL
Diabetes Mellitus, Type 2
Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Plasma Concentration Curve Zero to 10 Hours (AUC[0-10) Following Each Treatment Arm — 1380; 1280 hour times picomol…
Malaria
Primary: Successful Infection of Vector Mosquitoes Following Both Direct and Indirect Feeding on the Blood of Infected Participants
Smoking Cessation
Primary: Acceptability — 0; 0; 1; 0 Participants
Neoplasm Metastasis
Primary: Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs) — 0; 1; 0; 1 Participants
Healthy
Primary: Pharmacokinetics (PK) : Insulin Lispro Area Under the Concentration Curve Zero to Infinity (AUC[0-∞]) ) — 901; 1890; 3970; 1790 picomol per hour per L (pmol.h/L)
Psychosis
Primary: Rate of Conversion to Psychosis. — 4; 3 Participants — p=.51
Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) for PF-04965842 — 1352; 1276; 1426 nanogram per milliliter (ng/mL)
Healthy Subjects
Primary: AUC0-∞ of Eculizumab — 104346442.41; 114291981.79 (ng/ml)*hour
Diabetes Mellitus, Type 1
Primary: Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve (AUC) — 970; 968 picomoles times hour per Liter — p=0.7734
Healthy Male Subjects
Primary: AUC0-48 — 32.06; 6.491; 45.89; 30.14 ng*hr/mL
Healthy Volunteers
Primary: Part A: Pharmacokinetics (PK ): Area Under the Concentration Curve From Zero to the Last Recorded Time Post Dose (AUC0-tlast) — 1720; 1740; 1810; 1750 picomol times hour…